Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by an educational grant from Takeda Oncology.
BURST CME™: Deciphering Clinical Trial Endpoints Amidst an Advent of Novel Therapies for Low- to High-Risk MDS
Release Date: December 21, 2021
Expiration Date: December 21, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Takeda Oncology.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational program is directed toward hematologists and medical oncologists interested in the treatment of hematologic malignancies. Other allied healthcare professionals, including nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with hematologic malignancies will also be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to
- Summarize the criteria for myelodysplastic syndrome (MDS) treatment and response assessment utilized in clinical trials as endpoints
- Discuss endpoints utilized from recent clinical trials aimed at honing treatment in MDS based on risk stratification
- Evaluate recent efficacy and safety results from trials that assessed evolving approaches for MDS management
- Explain the clinical impact of recent trial findings in the context of trial endpoints and how they are shaping evolving treatment pathways in MDS care
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Faculty
Chief, Division of Hematology
Sylvester Comprehensive Cancer Center
University of Miami Health System
Miami, FL
Disclosures: Consultant: Celgene/Bristol Myers Squibb, Novartis, Pfizer, Syros Pharmaceuticals.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
